Oncolytics Biotech disengages EY, engages Baker Tilly as auditor after restructuring

ONCOLYTICS BIOTECH INC

Audit committee voted to disengage EY and engage Baker Tilly for fiscal 2026, subject to client acceptance.
EY's reports for 2024 and 2025 contained no adverse opinion but included a going-concern explanatory paragraph.
No disagreements or reportable events with EY during the fiscal years ended 2024 and 2025.
Company provided EY with a copy of the 8-K and requested a letter to the SEC regarding the statements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.